InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed To Present At Canaccord Genuity Conference

January 23, 2018

InMed Closes Over-Subscribed C$9.4 Million Financing

January 4, 2018

InMed Clarifies 3rd Party News Coverage

December 20, 2017

InMed Announces Non-Brokered Private Placement

December 18, 2017

InMed to Present at Cannabis-Based Science & Medicine Conference

November 16, 2017

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid

October 24, 2017

InMed Updates Pain Program

October 17, 2017

InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board

October 10, 2017

InMed Pharmaceuticals Files Provisional Patent for Pain Program

October 3, 2017

InMed Continues to Make Significant Strides on Biosynthesis Program Development

September 25, 2017

InMed Pharmaceuticals Added to CSE25 Index

September 21, 2017

InMed Retains Consultant Ben Paterson for Biosynthesis Development

September 19, 2017

InMed Files Provisional Patent for Biosynthesis of Cannabinoids

September 12, 2017

InMed Announces Appointment of Creative Capital Media

August 18, 2017

InMed Announces Publication in European Journal of Pain

July 27, 2017

InMed Signs R&D Agreement with ATERA

July 10, 2017

InMed Announces Agreement to Advance a Topical Formulation of INM-750

June 13, 2017

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

May 31, 2017

InMed Announces Pricing of $5,004,000 Underwritten Financing

May 23, 2017

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

May 10, 2017

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.